The Pfizer and BioNTech SE Covid-19 vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunisation will curb transmission of the coronavirus.
The vaccine, which was rolled out in a national immunisation program that began December 20, was 89.4 per cent effective at preventing laboratory-confirmed infections, according to a copy of a draft publication that was posted on Twitter and confirmed by a person familiar with the work. The companies and Israel’s Health Ministry worked together on the preliminary observational analysis, which has not yet been peer-reviewed.
The results, also reported in Der Spiegel, are the latest in a series of positive data to emerge out of Israel, which has given more Covid vaccines per capita than anywhere else in the world. Nearly half of the population has had at least one dose of vaccine. Separately, Israeli authorities on Saturday said the Pfizer-BioNTech shot was 99 per cent effective at preventing deaths from the virus.
The early results on lab-confirmed infections are important because they show the vaccine may also prevent asymptomatic carriers from spreading the virus that causes Covid-19, something that hadn’t been clear so far. Stopping transmission in this way is a key factor as countries seek to lift contact restrictions and re-open economies.
Pfizer and BioNTech said they are working on a real-world analysis of data from Israel, which will be shared as soon as it’s complete. Spokespeople declined to comment on unpublished data.
Four-fifths of the virus cases in Israel during the time period of the study, from January 17 to February 6, were the more transmissible strain first identified in the UK Israel’s vaccination drive began just before the so-called B.1.1.7 variant emerged, fueling infections and leading to a third lockdown on January 8.
Through February 6, about 27 per cent of people aged 15 and older in Israel were fully vaccinated, with the Pfizer-BioNTech shot the only vaccine available in the country at the time. People were considered fully vaccinated and included in the analysis if the data collected were more than 7 days after they received their second dose.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU